X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas Piramal: An update - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 2, 2003

    Nicholas Piramal: An update

    The recent bull run has been a broad based one with companies across sectors making strong gains. In the pharma sector, domestic major, Nicholas Piramal too has been making strong gains, which is evident from the following table. As can be seen from the table, Rs 100 invested in Nicholas Piramal and the BSE-Sensex on 1st April '03, would have yielded Rs 279 and Rs 164 respectively. In this article, we shall see what has changed for the company during the past eight months.

    To start with, let's look at Nicholas Piramal's half yearly results. Powered by a respectable growth in the domestic market, sharp export growth coupled with acquisition (Global Bulk Drugs and Fine Chemicals), the company recorded a 20% topline growth and a 27% growth in net profit during 1HFY04. This was impressive given the slump in the domestic pharma market during April '03 - June '03. Apart from the impressive performance, another positive for the company was the announcement of its alliance with Biogen Idec of USA for marketing in India of Biogen's 'Avonex', a leading life saving drug for multiple sclerosis. It is estimated that there are roughly 50,000 cases of multiple sclerosis in India. This translates into higher revenues for the company going forward.

    Nicholas Piramal has identified biotechnology as one of its key focus areas going forward apart from contract manufacturing. The company has strong marketing capabilities in oncology, nephrology, virology and critical care. The company already markets products for Gilead Sciences and Roche. Although Biotek segment contributed merely 6% to the company's FY03 earnings, it is expected to record impressive growth going forward.

    Contribution of Biotek segment
    (Rs m) 1HFY04 1HFY03 FY03
    Biotek 342 315 706
    Gross revenues 5,748 4,611 11,361
    % of gross revenues 5.9% 6.8% 6.2%

    While the impressive half yearly performance and the alliance are a positive for the company going forward, the news of the National Pharmaceutical Pricing Authority (NPPA) lowering the price of Vitamin A bulk drugs has certainly acted as a dampener. The NPPA has announced an 18% to 23% drop in prices. With Vitamins accounting for roughly 7% of the company's revenues, the performance of the company could be impacted in the short term, in view of this price reduction.

    At Rs 584 Nicholas Piramal is trading at a P/E of 15x annualised 1HFY04 earnings. Although the company has outperformed the industry in the domestic market, the uncertainty regarding the market scenario post the implementation of product patents in 2005 is a cause for concern. However, the company has been able to gradually increase its exports focus and de-risk its business from the vagaries of the domestic market. This apart, Nicholas Piramal's initiatives for becoming a partner of choice for contract manufacturing translate into good prospects for the company going forward. To this extent, we are optimistic about the prospects of the company.

     

     

    Equitymaster requests your view! Post a comment on "Nicholas Piramal: An update". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PIRAMAL ENTERPRISES SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK PIRAMAL ENTERPRISES

    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON PIRAMAL ENTERPRISES

    PIRAMAL ENTERPRISES 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE PIRAMAL ENTERPRISES WITH

    MARKET STATS